Single User
£3750
PDF
46 pages

Cachexia Forecast in 8 Major Markets 2016-2026


According to the most recent consensus statement (Muscaritoli et al 2010), cachexia can be defined as weight loss exceeding 5% within the previous 3-12 months in patients with long term chronic conditions OR BMI < 20 kg/m², combined with symptoms characteristic for cachexia, loss of skeletal muscle and biochemical abnormalities. While the same mechanisms that contribute to sarcopenia undoubtedly contribute to cachexia, in addition there are specific mechanisms that contribute to muscle wasting from an underlying pathology. These include: inflammation, in particular IL-6, IL-1 and TNF-α, and irregular protein metabolism. Patients with cachexia tend to burn more energy during their resting state than sarcopenic patients.

This report provides the current prevalent population Cachexia across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Cachexia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Key underlying pathologies linked with developing cachexia include:

  • COPD
  • CKD and end stage renal disease (ESRD)
  • CHF
  • Cancer
  • AIDS and HIV
  • Rheumatoid arthritis and other autoimmune conditions

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in the global Cachexia market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Cachexia and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Cachexia’s prevalent population.
  • Identify sub-populations within Cachexia which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Cachexia patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Cachexia
  • Features of Cachexia Patients
    • Aetiology of Cachexia Patients
    • COPD Patients with Cachexia
    • CKD Patients with Cachexia
    • CHF Patients with Cachexia
    • Cancer Patients with Cachexia
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
  List of Figures
  • Stages of cancer cachexia
  • Conceptual representation of the definition of cachexia
List of Tables
  • Difference between sarcopenia and cachexia
  • Leading cause of cachexia
  • Prevalence of Cachexia, total (000s)
  • Prevalence of Cachexia, , males (000s)
  • Prevalence of Cachexia, , females (000s)
  • Cachexia patients by aetiology, total (000s)
  • COPD Cachexia patients by GOLD stage. total (000s)
  • CKD Cachexia patients by CKD stage. total (000s)
  • CHF Cachexia patients by Ejection fraction HF type, total (000s)
  • Cancer Cachexia patients by cancer type, total (000s)
  • Digestive cancer Cachexic patients by cancer type, total (000s)
  • Haematological cancer Cachexic patients by cancer type, total (000s)
  • Head & Neck cancer cachexic patients by cancer type, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • USA Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • France Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • France Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • Germany Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • Germany Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • Italy Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • Italy Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • Spain Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • Spain Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • Japan Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • Japan Prevalence of Cachexia by 5-yr age cohort, females (000s)
Brazil, France, Germany, Italy, Japan, Spain, United Kingdom, United States of America